摘要
随着人口老龄化,心房颤动(房颤)患者增多,房颤相关卒中等并发症也有增多趋势,抗栓治疗远远不足,且风险和获益并存。临床应根据房颤卒中风险分层评估,单独或联合使用阿司匹林、华法林、利伐沙班等新型口服抗凝剂(NOAC),制订相应治疗方案,定期监测。随着NOAC的陆续上市,抗栓治疗可以有更多选择,对减少房颤相关卒中有积极影响。
With an aging population, there is an increased tendency in patients with atrial fibrillation, atrial fibrillation-related stroke and other complications. The antithrombotic therapy is not adequate, and coex- isting with both benefits and potential risks. Thus, in clinical assessment based on atrial fibrillation stroke risk stratification should be done, alone or in combination with novel oral anticoagulants such as aspirin, warfarin and rivaroxaban appropriate treatment programs with regular monitoring should be developed. With more novel oral anticoagulants going into the medicine market, there are more options for antithrombotic therapy, which brings positive influence on the reduction of atrial fibrillation-related stroke.
出处
《医学综述》
2014年第5期849-852,共4页
Medical Recapitulate
关键词
心房颤动
卒中
抗凝药
Atrial fibrillation
Stroke
Anticoagulants
